Imperva Inc (IMPV.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Imperva Inc gives Q3 2014 guidance in line with analysts' estimates; raises FY 2014 guidance


Thursday, 31 Jul 2014 04:11pm EDT 

Imperva Inc:Expects Q3 2014 total revenue to be in the range of $38.0 million to $41.0 million.Expects Q3 2014 non-GAAP operating loss to be in the range of $(6.0) million to $(8.0) million.Expects Q3 2014 non-GAAP net loss attributable to Imperva stockholders to be in the range of $(6.5) million to $(8.5) million, or a loss of $(0.25) to $(0.33) per share.Expects FY 2014 total revenue to be in the range of $155.5 million to $162.5 million.Expects FY 2014 non-GAAP operating loss to be in the range of $(21.0) million to $(26.5) million.Expects FY 2014 non-GAAP net loss attributable to Imperva stockholders to be in the range of $(21.5) million to $(27.5) million, or a loss of $(0.83) to $(1.06) per share.Q3 2014 revenue of $40 million, EBIT of $(7) million, net income of $(7.6) million and EPS of $(0.28) - Thomson Reuters I/B/E/S.FY 2014 revenue of $154 million, EBIT of $(29.5) million, net income of $(30.2) million and EPS of $(1.14) - Thomson Reuters I/B/E/S.